Date Title Document
Valeant Appoints William D. Humphries As EVP, Dermatology Date 12/12/16 Title Valeant Appoints William D. Humphries As EVP, Dermatology Download PDF
Valeant Pharmaceuticals Announces Phase 3 Results For Psoriasis Treatment IDP-118 Date 12/08/16 Title Valeant Pharmaceuticals Announces Phase 3 Results For Psoriasis Treatment IDP-118 Download PDF
Valeant Announces The Initiation Of A Primary Care Sales Force For Xifaxan® And Relistor® Date 11/29/16 Title Valeant Announces The Initiation Of A Primary Care Sales Force For Xifaxan® And Relistor® Download PDF
Valeant Comments On Issued Philidor Criminal Charges Date 11/17/16 Title Valeant Comments On Issued Philidor Criminal Charges Download PDF
Valeant Pharmaceuticals To Participate In Healthcare Conferences Date 11/10/16 Title Valeant Pharmaceuticals To Participate In Healthcare Conferences Download PDF
Valeant Reports Third Quarter 2016 Financial Results Date 11/08/16 Title Valeant Reports Third Quarter 2016 Financial Results Download pdf
Valeant Pharmaceuticals Comments On Press Report Regarding Its Gastroenterology Business Unit Date 11/01/16 Title Valeant Pharmaceuticals Comments On Press Report Regarding Its Gastroenterology Business Unit Download PDF
Valeant Pharmaceuticals Comments On Press Report Date 10/31/16 Title Valeant Pharmaceuticals Comments On Press Report Download PDF
Valeant Announces Third Quarter Financial Results Date And Conference Call Details Date 10/17/16 Title Valeant Announces Third Quarter Financial Results Date And Conference Call Details Download PDF
Valeant Patient Access And Pricing Committee Comments On Recent Pricing Action Decisions Date 10/14/16 Title Valeant Patient Access And Pricing Committee Comments On Recent Pricing Action Decisions Download PDF
Valeant Appoints Louis W. Yu, Ph.D. As Chief Quality Officer Date 10/06/16 Title Valeant Appoints Louis W. Yu, Ph.D. As Chief Quality Officer Download PDF
Valeant Comments On Discount And Rebate Program For Nitropress And Isuprel Date 09/16/16 Title Valeant Comments On Discount And Rebate Program For Nitropress And Isuprel Download PDF
Valeant And Progenics Announce The U.S. Commercial Launch Of FDA-Approved Relistor® Tablets Date 09/06/16 Title Valeant And Progenics Announce The U.S. Commercial Launch Of FDA-Approved Relistor® Tablets Download PDF
Valeant Pharmaceuticals To Participate In September Healthcare Conferences Date 08/30/16 Title Valeant Pharmaceuticals To Participate In September Healthcare Conferences Download PDF
Valeant Pharmaceuticals Appoints Paul S. Herendeen As Executive Vice President, Finance And Chief Financial Officer Date 08/22/16 Title Valeant Pharmaceuticals Appoints Paul S. Herendeen As Executive Vice President, Finance And Chief Financial Officer Download PDF
Valeant Pharmaceuticals Receives Lender Consent For Credit Facility Amendment Date 08/18/16 Title Valeant Pharmaceuticals Receives Lender Consent For Credit Facility Amendment Download PDF
Valeant Pharmaceuticals Comments On SDNY Investigation Date 08/10/16 Title Valeant Pharmaceuticals Comments On SDNY Investigation Download PDF
Valeant Pharmaceuticals Reports Second Quarter 2016 Financial Results Date 08/09/16 Title Valeant Pharmaceuticals Reports Second Quarter 2016 Financial Results Download PDF
Valeant Pharmaceuticals Announces Significant Support For Education And Research Regarding Wilson Disease Date 08/08/16 Title Valeant Pharmaceuticals Announces Significant Support For Education And Research Regarding Wilson Disease Download PDF
Valeant Pharmaceuticals Announces Relaunch Of Generic Ofloxacin Otic Solution Date 08/08/16 Title Valeant Pharmaceuticals Announces Relaunch Of Generic Ofloxacin Otic Solution Download PDF
Valeant Pharmaceuticals Announces Licensing Agreement With Norgine B.V. For NER1006 In U.S. And Canada Date 08/08/16 Title Valeant Pharmaceuticals Announces Licensing Agreement With Norgine B.V. For NER1006 In U.S. And Canada Download PDF
Valeant Pharmaceuticals Announces Changes To Executive Management Team Date 08/08/16 Title Valeant Pharmaceuticals Announces Changes To Executive Management Team Download PDF
Valeant Pharmaceuticals Announces The Addition Of Sarah B. Kavanagh To Its Board Of Directors Date 07/28/16 Title Valeant Pharmaceuticals Announces The Addition Of Sarah B. Kavanagh To Its Board Of Directors Download PDF
Valeant Pharmaceuticals Receives Complete Response Letter From The FDA Date 07/22/16 Title Valeant Pharmaceuticals Receives Complete Response Letter From The FDA Download PDF
Valeant and Progenics Announce FDA Approves RELISTOR® Tablets for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-cancer Pain Date 07/19/16 Title Valeant and Progenics Announce FDA Approves RELISTOR® Tablets for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-cancer Pain Download PDF
FDA Advisory Committee Recommends Approval Of Brodalumab For Treatment Of Moderate-To-Severe Plaque Psoriasis Date 07/19/16 Title FDA Advisory Committee Recommends Approval Of Brodalumab For Treatment Of Moderate-To-Severe Plaque Psoriasis Download PDF
Valeant Pharmaceuticals Announces Second Quarter Results Conference Call Date And Details Date 07/15/16 Title Valeant Pharmaceuticals Announces Second Quarter Results Conference Call Date And Details Download PDF
Valeant Pharmaceuticals Comments On Recent Stock Transactions Date 07/14/16 Title Valeant Pharmaceuticals Comments On Recent Stock Transactions Download PDF
Bausch + Lomb and Nicox Announce the Publication of Latanoprostene Bunod Ophthalmic Solution 0.024% Phase 3 Study Results in American Journal of Ophthalmology Date 07/06/16 Title Bausch + Lomb and Nicox Announce the Publication of Latanoprostene Bunod Ophthalmic Solution 0.024% Phase 3 Study Results in American Journal of Ophthalmology Download PDF
Valeant Pharmaceuticals Announces New Licensing Arrangement For Brodalumab In Europe Date 07/01/16 Title Valeant Pharmaceuticals Announces New Licensing Arrangement For Brodalumab In Europe Download PDF
Canadian Shopper Study Names Bausch + Lomb Most Trusted Brand For Contact Lens Care Date 06/27/16 Title Canadian Shopper Study Names Bausch + Lomb Most Trusted Brand For Contact Lens Care Download PDF
Valeant Pharmaceuticals Announces Significant Investments In Canadian Operations Date 06/17/16 Title Valeant Pharmaceuticals Announces Significant Investments In Canadian Operations Download PDF
Valeant Pharmaceuticals Announces Launch Of New PreserVision® AREDS 2 Formula + Multivitamin Date 06/16/16 Title Valeant Pharmaceuticals Announces Launch Of New PreserVision® AREDS 2 Formula + Multivitamin Download PDF
Valeant Pharmaceuticals Appoints Thomas W. Ross, Sr. Lead Independent Director Date 06/15/16 Title Valeant Pharmaceuticals Appoints Thomas W. Ross, Sr. Lead Independent Director Download PDF
Valeant To Participate In FDA Advisory Committee Meeting On July 19 Date 06/09/16 Title Valeant To Participate In FDA Advisory Committee Meeting On July 19 Download PDF
Valeant Pharmaceuticals To Webcast 2016 Annual Meeting Of Shareholders Date 06/07/16 Title Valeant Pharmaceuticals To Webcast 2016 Annual Meeting Of Shareholders Download PDF
Valeant Pharmaceuticals Reports First Quarter 2016 Financial Results Date 06/07/16 Title Valeant Pharmaceuticals Reports First Quarter 2016 Financial Results Download PDF
Valeant Pharmaceuticals Receives Additional Notice Of Default Under Indentures Due To Delayed Form 10-Q Filing Date 06/03/16 Title Valeant Pharmaceuticals Receives Additional Notice Of Default Under Indentures Due To Delayed Form 10-Q Filing Download PDF
Valeant Pharmaceuticals To Present Six Abstracts At 2016 ASCO Annual Meeting Date 06/01/16 Title Valeant Pharmaceuticals To Present Six Abstracts At 2016 ASCO Annual Meeting Download PDF
Valeant Pharmaceuticals To Hold Conference Call On June 7, 2016 Date 05/31/16 Title Valeant Pharmaceuticals To Hold Conference Call On June 7, 2016 Download PDF
Valeant Pharmaceuticals Names Sam Eldessouky Senior Vice President And Corporate Controller Date 05/26/16 Title Valeant Pharmaceuticals Names Sam Eldessouky Senior Vice President And Corporate Controller Download PDF
Bausch + Lomb Wins Walmart "Supplier of the Year" Award Date 05/23/16 Title Bausch + Lomb Wins Walmart "Supplier of the Year" Award Download PDF
Valeant Pharmaceuticals Receives Notice Of Default From Bondholders Date 05/19/16 Title Valeant Pharmaceuticals Receives Notice Of Default From Bondholders Download PDF
Valeant Pharmaceuticals To Participate At The UBS Global Healthcare Conference Date 05/18/16 Title Valeant Pharmaceuticals To Participate At The UBS Global Healthcare Conference Download PDF
Valeant Pharmaceuticals Provides Update Regarding Regulatory Matters Date 05/16/16 Title Valeant Pharmaceuticals Provides Update Regarding Regulatory Matters Download PDF
Valeant Pharmaceuticals Announces Expanded Discounts For Nitropress And Isuprel Date 05/16/16 Title Valeant Pharmaceuticals Announces Expanded Discounts For Nitropress And Isuprel Download PDF
Valeant Pharmaceuticals Announces Expected Timing Of Form 10-Q Filing And Reiterates 2016 First Quarter Guidance Date 05/09/16 Title Valeant Pharmaceuticals Announces Expected Timing Of Form 10-Q Filing And Reiterates 2016 First Quarter Guidance Download PDF
Valeant Pharmaceuticals Announces Patient Access And Pricing Committee To Oversee Pricing Of Drugs Date 05/05/16 Title Valeant Pharmaceuticals Announces Patient Access And Pricing Committee To Oversee Pricing Of Drugs Download PDF
Valeant Pharmaceuticals Announces Collaboration Between Bausch + Lomb And IBM Date 05/05/16 Title Valeant Pharmaceuticals Announces Collaboration Between Bausch + Lomb And IBM Download PDF
Joseph C. Papa Assumes Role Of Chairman And Chief Executive Officer Of Valeant Pharmaceuticals Date 05/03/16 Title Joseph C. Papa Assumes Role Of Chairman And Chief Executive Officer Of Valeant Pharmaceuticals Download PDF
Valeant Announces Nominees For Election To Board Of Directors Date 04/29/16 Title Valeant Announces Nominees For Election To Board Of Directors Download PDF
Valeant Pharmaceuticals Files Annual Report On Form 10-K For Year Ended December 31, 2015 Date 04/29/16 Title Valeant Pharmaceuticals Files Annual Report On Form 10-K For Year Ended December 31, 2015 Download PDF
Valeant Names Joseph C. Papa To Be Chairman And Chief Executive Officer Of Valeant Pharmaceuticals Date 04/25/16 Title Valeant Names Joseph C. Papa To Be Chairman And Chief Executive Officer Of Valeant Pharmaceuticals Download PDF
Valeant Pharmaceuticals Receives Additional Notices Of Default Under Indentures Due To Delayed 10-K Filing Date 04/22/16 Title Valeant Pharmaceuticals Receives Additional Notices Of Default Under Indentures Due To Delayed 10-K Filing Download PDF
Valeant Pharmaceuticals Provides Update Regarding Regulatory Matters Date 04/13/16 Title Valeant Pharmaceuticals Provides Update Regarding Regulatory Matters Download PDF
Valeant Pharmaceuticals Receives Notice Of Default From Bondholders Due To Delayed 10-K Filing Date 04/12/16 Title Valeant Pharmaceuticals Receives Notice Of Default From Bondholders Due To Delayed 10-K Filing Download PDF
Valeant Board Of Directors Issues Statement On J. Michael Pearson's Cooperation With Senate Committee on Aging Date 04/11/16 Title Valeant Board Of Directors Issues Statement On J. Michael Pearson's Cooperation With Senate Committee on Aging Download PDF
Valeant Pharmaceuticals Receives Lender Consent For Credit Facility Amendment Date 04/07/16 Title Valeant Pharmaceuticals Receives Lender Consent For Credit Facility Amendment Download PDF
Valeant Ad Hoc Committee Announces Completion Of Its Review Of Philidor And Related Accounting Matters Date 04/05/16 Title Valeant Ad Hoc Committee Announces Completion Of Its Review Of Philidor And Related Accounting Matters Download PDF
Valeant and Progenics Announce PDUFA Date Extension for Oral RELISTOR Date 04/04/16 Title Valeant and Progenics Announce PDUFA Date Extension for Oral RELISTOR Download PDF
Valeant Pharmaceuticals Launches Credit Facility Amendment Date 03/30/16 Title Valeant Pharmaceuticals Launches Credit Facility Amendment Download PDF
Valeant Announces CEO Succession Plan And Changes To Board Of Directors; Provides Accounting And Financial Reporting Update Date 03/21/16 Title Valeant Announces CEO Succession Plan And Changes To Board Of Directors; Provides Accounting And Financial Reporting Update Download PDF
/C O R R E C T I O N -- Valeant Pharmaceuticals International, Inc./ Date 03/15/16 Title /C O R R E C T I O N -- Valeant Pharmaceuticals International, Inc./ Download PDF
Valeant And R&O Pharmacy End Litigation Date 03/09/16 Title Valeant And R&O Pharmacy End Litigation Download PDF
Valeant Pharmaceuticals Announces The Addition Of Three New Independent Directors To Its Board Date 03/09/16 Title Valeant Pharmaceuticals Announces The Addition Of Three New Independent Directors To Its Board Download PDF
Valeant Pharmaceuticals To Hold Conference Call On March 15, 2016 Date 03/07/16 Title Valeant Pharmaceuticals To Hold Conference Call On March 15, 2016 Download PDF
Valeant Pharmaceuticals Comments On Management Change Date 03/03/16 Title Valeant Pharmaceuticals Comments On Management Change Download PDF
Valeant Pharmaceuticals Announces Management Change Date 03/02/16 Title Valeant Pharmaceuticals Announces Management Change Download PDF
Valeant Pharmaceuticals Announces Management And Business Update Date 02/28/16 Title Valeant Pharmaceuticals Announces Management And Business Update Download PDF
Valeant Ad Hoc Committee has Made Substantial Progress in Its Review of Philidor and Related Accounting Matters Date 02/22/16 Title Valeant Ad Hoc Committee has Made Substantial Progress in Its Review of Philidor and Related Accounting Matters Download PDF
Valeant Announces FDA Acceptance of BLA Submission for Brodalumab in Moderate-to-Severe Plaque Psoriasis Date 01/25/16 Title Valeant Announces FDA Acceptance of BLA Submission for Brodalumab in Moderate-to-Severe Plaque Psoriasis Download PDF
Valeant Provides Update On J. Michael Pearson Date 01/25/16 Title Valeant Provides Update On J. Michael Pearson Download PDF
Valeant Names Howard B. Schiller Interim CEO Date 01/06/16 Title Valeant Names Howard B. Schiller Interim CEO Download PDF
Valeant Pharmaceuticals To Present At The 34th Annual J.P. Morgan Healthcare Conference Date 01/04/16 Title Valeant Pharmaceuticals To Present At The 34th Annual J.P. Morgan Healthcare Conference Download PDF
Annual Report

2015 Annual Report

The right products
The right philosophy.
record organic growth.

View All